Lila Levinson, PhD,  Science Writer—

Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.

Articles by Lila Levinson, PhD

Underweight infants with PH at high risk for eye disease: Study

Underweight infants with pulmonary hypertension (PH) are at increased risk of developing retinopathy of prematurity (ROP), a leading cause of childhood blindness, according to a study. However, the prevalence of severe ROP was 18% lower in PH infants who received treatment with inhaled nitric oxide (iNO). “While iNO is…

Device can detect PH missed by other testing methods: Case series

Corvista Health’s point-of-care device can detect cases of pulmonary hypertension (PH) that other noninvasive diagnostic tools miss, according to a recent case series. “By enabling physicians to identify pulmonary hypertension within minutes, non-invasively, and even when traditional tests fail, we are offering a new standard of care that…

Lung transplant referrals lacking for PAH patients: Study

Most people with pulmonary arterial hypertension (PAH) are not referred for a lung transplant, despite clinical recommendations that referral should occur early in potentially eligible cases, a study reports. About 18% to 29% of participants with advanced functional class 4 disease, who guidelines recommend referrals for, received referrals.

Study suggests BMPER protein as treatment target in PAH

Providing a protein called BMPER that is found at low levels in models of pulmonary arterial hypertension (PAH) may ease disease progression, a study suggests. “Our study identifies BMPER as a novel therapeutic target for pulmonary arterial hypertension and provides new insights into the underlying mechanisms of the disease,” researchers wrote.

TPIP may improve circulation, exercise capacity in PAH: Study

A Phase 2b clinical trial of Insmed’s treprostinil palmitil inhalation powder (TPIP) suggested daily doses of the inhaled dry powder are well tolerated and may improve blood flow and exercise capacity in adults with pulmonary arterial hypertension (PAH). “The statistically significant and clinically meaningful results shown with TPIP…

HB-1614 may increase exercise capacity in PH-ILD: Clinical trial

A Phase 2a study of HB-1614, an oral therapy candidate, suggested the medication is safe and may improve exercise capacity and quality of life in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This is according to Halo Biosciences, developer of HB-1614, which announced the publication of…